Your browser is no longer supported. Please, upgrade your browser.
NVS [NYSE]
Novartis AG
Index- P/E19.61 EPS (ttm)4.34 Insider Own9.30% Shs Outstand2.24B Perf Week-5.99%
Market Cap211.70B Forward P/E12.86 EPS next Y6.62 Insider Trans0.00% Shs Float2.15B Perf Month-1.37%
Income9.81B PEG3.04 EPS next Q1.42 Inst Own10.00% Short Float0.34% Perf Quarter0.25%
Sales52.38B P/S4.04 EPS this Y14.20% Inst Trans-0.15% Short Ratio2.95 Perf Half Y-6.41%
Book/sh25.38 P/B3.35 EPS next Y4.50% ROA7.90% Target Price101.40 Perf Year-13.55%
Cash/sh3.28 P/C25.94 EPS next 5Y6.45% ROE18.00% 52W Range79.34 - 98.52 Perf YTD-2.68%
Dividend3.20 P/FCF33.16 EPS past 5Y4.10% ROI8.80% 52W High-13.76% Beta0.58
Dividend %3.76% Quick Ratio0.60 Sales past 5Y-0.20% Gross Margin70.60% 52W Low7.09% ATR1.28
Employees108000 Current Ratio0.90 Sales Q/Q6.60% Oper. Margin22.50% RSI (14)37.70 Volatility1.27% 0.97%
OptionableYes Debt/Eq0.60 EPS Q/Q45.60% Profit Margin18.70% Rel Volume1.04 Prev Close85.13
ShortableYes LT Debt/Eq0.44 EarningsFeb 02 BMO Payout70.70% Avg Volume2.50M Price84.96
Recom2.00 SMA20-3.96% SMA500.34% SMA200-2.85% Volume2,123,086 Change-0.19%
Jan-10-22Resumed Citigroup Buy
Dec-14-21Downgrade Redburn Buy → Neutral
Dec-06-21Downgrade Exane BNP Paribas Outperform → Neutral
Dec-03-21Downgrade Bryan Garnier Buy → Neutral
Sep-20-21Downgrade Deutsche Bank Hold → Sell
Mar-22-21Initiated Bernstein Mkt Perform
Mar-10-21Downgrade Argus Buy → Hold
Feb-01-21Downgrade Cowen Outperform → Market Perform $110 → $105
Jan-15-21Initiated Deutsche Bank Buy
Sep-29-20Initiated Berenberg Buy
Sep-10-20Upgrade UBS Neutral → Buy
Sep-01-20Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-15-20Upgrade Citigroup Neutral → Buy
Mar-10-20Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-20Downgrade Guggenheim Buy → Neutral
Apr-25-19Upgrade Liberum Hold → Buy
Apr-25-19Upgrade Guggenheim Neutral → Buy
Apr-10-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19Downgrade JP Morgan Neutral → Underweight
Dec-11-18Resumed Jefferies Buy
Jan-25-22 12:33PM  
Jan-23-22 02:28AM  
Jan-21-22 05:38PM  
05:38PM  
Jan-20-22 10:09AM  
Jan-19-22 09:38PM  
12:25PM  
Jan-18-22 09:38AM  
09:07AM  
Jan-17-22 09:44AM  
Jan-15-22 07:50AM  
Jan-14-22 01:38PM  
12:32PM  
09:38AM  
Jan-13-22 02:34PM  
Jan-12-22 01:38PM  
06:20AM  
Jan-11-22 11:37AM  
Jan-10-22 06:51PM  
09:32AM  
07:13AM  
06:41AM  
06:00AM  
05:46AM  
03:35AM  
01:15AM  
Jan-07-22 04:49PM  
Jan-05-22 11:48AM  
11:20AM  
09:38AM  
Jan-04-22 01:42AM  
01:15AM  
Dec-26-21 09:31AM  
Dec-24-21 09:13AM  
Dec-23-21 11:57AM  
11:22AM  
08:21AM  
08:20AM  
Dec-22-21 09:00PM  
06:00PM  
04:05PM  
12:13PM  
09:44AM  
09:12AM  
08:09AM  
02:00AM  
01:15AM  
Dec-21-21 10:42AM  
Dec-20-21 04:05PM  
10:15AM  
09:02AM  
07:22AM  
06:25AM  
06:15AM  
01:15AM  
Dec-16-21 12:20PM  
08:15AM  
05:51AM  
04:11AM  
03:40AM  
01:33AM  
01:15AM  
01:00AM  
Dec-15-21 09:01PM  
Dec-14-21 11:38PM  
12:16PM  
Dec-13-21 02:45PM  
Dec-11-21 04:00PM  
12:00PM  
08:40AM  
08:10AM  
Dec-10-21 08:02AM  
08:00AM  
12:02AM  
Dec-09-21 11:21AM  
08:08AM  
Dec-08-21 09:30AM  
08:19AM  
05:37AM  
Dec-07-21 09:50AM  
Dec-03-21 10:18AM  
10:11AM  
Dec-02-21 04:10PM  
02:13PM  
12:16PM  
09:01AM  
01:29AM  
01:15AM  
Dec-01-21 11:53AM  
06:30AM  
Nov-30-21 02:29PM  
08:07AM  
Nov-29-21 11:40AM  
Nov-26-21 05:18AM  
Nov-25-21 05:55AM  
Nov-23-21 11:52AM  
06:23AM  
Nov-21-21 11:00AM  
Nov-19-21 11:16AM  
10:45AM  
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.